Tezepelumab for Severe Asthma
Author Information
Author(s): Wechsler Michael E., Brusselle Guy, Virchow J. Christian, Bourdin Arnaud, Kostikas Konstantinos, Llanos Jean-Pierre, Roseti Stephanie L., Ambrose Christopher S., Hunter Gillian, Jackson David J., Castro Mario, Lugogo Njira, Pavord Ian D., Martin Neil, Brightling Christopher E.
Primary Institution: National Jewish Health, Denver, CO, USA
Hypothesis
Tezepelumab treatment improves clinical response and remission in patients with severe, uncontrolled asthma.
Conclusion
Tezepelumab treatment significantly increases the likelihood of achieving clinical response and remission in patients with severe asthma compared to placebo.
Supporting Evidence
- 46% of tezepelumab recipients achieved complete clinical response compared to 24% of placebo recipients.
- 28.5% of tezepelumab recipients achieved on-treatment clinical remission over the first year.
- 33.5% of tezepelumab recipients achieved on-treatment clinical remission over the second year.
Takeaway
Tezepelumab helps people with severe asthma feel better and stay better for a longer time compared to those who don't take it.
Methodology
The study involved two phase 3, randomized, double-blind, placebo-controlled trials assessing tezepelumab's effects on clinical response and remission in patients with severe asthma.
Potential Biases
Potential bias due to missing data and the influence of the pandemic on patient outcomes.
Limitations
The study's findings may be influenced by the COVID-19 pandemic, which affected data collection and exacerbation rates.
Participant Demographics
Patients aged 12-80 years with severe, uncontrolled asthma, including those with varying blood eosinophil counts.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 2.10–3.82
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website